Merck and partner Ridgeback Biotherapeutics said on Friday six lab studies showed that their experimental oral COVID-19 drug, molnupiravir, was active against the Omicron variant.
Merck's COVID-19 pill effective against Omicron in lab studies
By REUTERS
11/25/2024 01:29 AM
By REUTERS
11/24/2024 09:11 PM
By REUTERS
11/24/2024 06:51 PM
By REUTERS
11/24/2024 05:13 PM
By REUTERS
11/24/2024 03:21 PM
By REUTERS
11/24/2024 01:09 PM